Indications: Treatment of HIV infection in combination with other agents. Contraindications: Known hypersensitivity, history of pancreatitis or significant peripheral neuropathy. Dosage: Enteric-coated formulation (Videx EC) has been approved by the FDA for once daily dosing and can be given without regard to meals. Dose is 400 mg po qd for weight 60 kg and 250 mg po qd for weight 60 kg. Also available in tablets and buffered powder. Tablets: 60 kg -- 400 mg po qd or 200 mg po bid; 60 kg -- 250 mg po qd or 125 mg po bid. Tablets must be chewed or dissolved in water. Buffered Powder: 60 kg -- 250 mg po bid ; 60 kg -- 167 mg po bid. All formulations must be taken on an empty stomach ( 30 minutes before a meal or 2 hours after a meal). Coadministration of hydroxyurea 500 mg po bid may enhance the effectiveness of ddI by increasing intracellular level of drug. Toxicity: Peripheral neuropathy, acute pancreatitis, gastrointestinal intolerance, abnormal liver function tests. Pregnancy category B.